Novartis AG - Free Cash Flow To The Firm

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Free-Cash-Flow-To-The-Firm" stands at 19.29 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Novartis AG's third quarter result of 5.99 Billion USD for the item "Free Cash Flow To The Firm" represents a decrease of -5.99 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 5.99 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 4.63 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 19.29 Billion USD for the item "Free Cash Flow To The Firm" represents an increase of 1.39 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 40.26 percent compared to the value the year prior.
The 1 year change in percent is 40.26.
The 3 year change in percent is 64.73.
The 5 year change in percent is 64.29.
The 10 year change in percent is 95.55.

The Serie's long term average value is 11.80 Billion United States Dollars. It's latest available value, on 09/30/2025, is 63.42 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2016, to it's latest available value, on 09/30/2025, is +128.01%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.